KRAS mutation testing in human cancers

The pathologist's role in the Era of personalized medicine

Hanlin L. Wang, Jean Lopategui, Mahul Amin, Scott D. Patterson

Research output: Contribution to journalReview article

69 Citations (Scopus)

Abstract

A number of studies have shown that although antiepidermal growth factor receptor (EGFR) monoclonal antibodies are effective treatments for metastatic colorectal cancer (mCRC), only patients with wild-type KRAS tumors derive clinical benefit from these therapies. The anti-EGFR monoclonal antibodies panitumumab and cetuximab are approved in the United States for treatment of mCRC refractory to chemotherapy but are not recommended for use in patients with mutations in KRAS codons 12 or 13. Similarly, panitumumab is approved for the treatment of mCRC only in patients with wild-type KRAS in Europe and Canada. It is clear that KRAS mutational analysis will become an important aspect of disease management in patients with mCRC. Consequently, it will be important for pathologists and oncologists to develop and agree on standardized KRAS testing and reporting procedures to ensure optimum patient care. Pathologists will be central to this process because of their crucial role in selecting appropriate tumor specimens for testing, choosing the molecular diagnostic laboratory to be used, assisting in the selection of a suitable KRAS test, and interpreting the results of KRAS mutational analysis. Guidelines for KRAS testing that address these and other important points of consideration have recently been proposed in the United States and the European Union.

Original languageEnglish (US)
Pages (from-to)23-32
Number of pages10
JournalAdvances in Anatomic Pathology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Precision Medicine
Colorectal Neoplasms
Mutation
Neoplasms
Molecular Diagnostic Techniques
Monoclonal Antibodies
Growth Factor Receptors
European Union
Therapeutics
Disease Management
Codon
Canada
Patient Care
Guidelines
Drug Therapy
Pathologists
panitumumab

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

KRAS mutation testing in human cancers : The pathologist's role in the Era of personalized medicine. / Wang, Hanlin L.; Lopategui, Jean; Amin, Mahul; Patterson, Scott D.

In: Advances in Anatomic Pathology, Vol. 17, No. 1, 01.01.2010, p. 23-32.

Research output: Contribution to journalReview article

Wang, Hanlin L. ; Lopategui, Jean ; Amin, Mahul ; Patterson, Scott D. / KRAS mutation testing in human cancers : The pathologist's role in the Era of personalized medicine. In: Advances in Anatomic Pathology. 2010 ; Vol. 17, No. 1. pp. 23-32.
@article{088e810004a246c09f7291b53892e415,
title = "KRAS mutation testing in human cancers: The pathologist's role in the Era of personalized medicine",
abstract = "A number of studies have shown that although antiepidermal growth factor receptor (EGFR) monoclonal antibodies are effective treatments for metastatic colorectal cancer (mCRC), only patients with wild-type KRAS tumors derive clinical benefit from these therapies. The anti-EGFR monoclonal antibodies panitumumab and cetuximab are approved in the United States for treatment of mCRC refractory to chemotherapy but are not recommended for use in patients with mutations in KRAS codons 12 or 13. Similarly, panitumumab is approved for the treatment of mCRC only in patients with wild-type KRAS in Europe and Canada. It is clear that KRAS mutational analysis will become an important aspect of disease management in patients with mCRC. Consequently, it will be important for pathologists and oncologists to develop and agree on standardized KRAS testing and reporting procedures to ensure optimum patient care. Pathologists will be central to this process because of their crucial role in selecting appropriate tumor specimens for testing, choosing the molecular diagnostic laboratory to be used, assisting in the selection of a suitable KRAS test, and interpreting the results of KRAS mutational analysis. Guidelines for KRAS testing that address these and other important points of consideration have recently been proposed in the United States and the European Union.",
author = "Wang, {Hanlin L.} and Jean Lopategui and Mahul Amin and Patterson, {Scott D.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1097/PAP.0b013e3181c6962f",
language = "English (US)",
volume = "17",
pages = "23--32",
journal = "Advances in Anatomic Pathology",
issn = "1072-4109",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - KRAS mutation testing in human cancers

T2 - The pathologist's role in the Era of personalized medicine

AU - Wang, Hanlin L.

AU - Lopategui, Jean

AU - Amin, Mahul

AU - Patterson, Scott D.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - A number of studies have shown that although antiepidermal growth factor receptor (EGFR) monoclonal antibodies are effective treatments for metastatic colorectal cancer (mCRC), only patients with wild-type KRAS tumors derive clinical benefit from these therapies. The anti-EGFR monoclonal antibodies panitumumab and cetuximab are approved in the United States for treatment of mCRC refractory to chemotherapy but are not recommended for use in patients with mutations in KRAS codons 12 or 13. Similarly, panitumumab is approved for the treatment of mCRC only in patients with wild-type KRAS in Europe and Canada. It is clear that KRAS mutational analysis will become an important aspect of disease management in patients with mCRC. Consequently, it will be important for pathologists and oncologists to develop and agree on standardized KRAS testing and reporting procedures to ensure optimum patient care. Pathologists will be central to this process because of their crucial role in selecting appropriate tumor specimens for testing, choosing the molecular diagnostic laboratory to be used, assisting in the selection of a suitable KRAS test, and interpreting the results of KRAS mutational analysis. Guidelines for KRAS testing that address these and other important points of consideration have recently been proposed in the United States and the European Union.

AB - A number of studies have shown that although antiepidermal growth factor receptor (EGFR) monoclonal antibodies are effective treatments for metastatic colorectal cancer (mCRC), only patients with wild-type KRAS tumors derive clinical benefit from these therapies. The anti-EGFR monoclonal antibodies panitumumab and cetuximab are approved in the United States for treatment of mCRC refractory to chemotherapy but are not recommended for use in patients with mutations in KRAS codons 12 or 13. Similarly, panitumumab is approved for the treatment of mCRC only in patients with wild-type KRAS in Europe and Canada. It is clear that KRAS mutational analysis will become an important aspect of disease management in patients with mCRC. Consequently, it will be important for pathologists and oncologists to develop and agree on standardized KRAS testing and reporting procedures to ensure optimum patient care. Pathologists will be central to this process because of their crucial role in selecting appropriate tumor specimens for testing, choosing the molecular diagnostic laboratory to be used, assisting in the selection of a suitable KRAS test, and interpreting the results of KRAS mutational analysis. Guidelines for KRAS testing that address these and other important points of consideration have recently been proposed in the United States and the European Union.

UR - http://www.scopus.com/inward/record.url?scp=75449087691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75449087691&partnerID=8YFLogxK

U2 - 10.1097/PAP.0b013e3181c6962f

DO - 10.1097/PAP.0b013e3181c6962f

M3 - Review article

VL - 17

SP - 23

EP - 32

JO - Advances in Anatomic Pathology

JF - Advances in Anatomic Pathology

SN - 1072-4109

IS - 1

ER -